Alopecia Areata Lesions Show Significant Changes In Immune And Keratin Biomarkers That Correlate With Clinical Improvement With Oral Janus Kinase Inhibitors PF-06651600 (JAK3) And PF-06700841 (TYK2/JAK1)
April 2019
in “
Journal of Investigative Dermatology
”
Studysummary This study found that oral JAK3 and TYK2/JAK1 inhibitors improved clinical outcomes in alopecia areata patients by reducing immune responses and enhancing hair keratin expression, with stronger effects in those with shorter disease duration.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on jidonline.org →